Zhitong Finance App News, Fengyuan Pharmaceutical (000153.SZ) issued an announcement. Recently, Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Approval of the Marketing Application for Chemical Ingredients” with the approval and issuance of tirofiban hydrochloride by the State Drug Administration.

Tirofiban hydrochloride is a reversible antagonist that binds fibrinogen to GpIIB/IIa receptors on platelet surface. Intravenous administration can inhibit platelet aggregation and is used in adult patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) to reduce the risk of ischemic events such as early myocardial infarction; it can also be used in ST-segment elevation acute myocardial infarction (STEMI) patients receiving percutaneous coronary intervention (PCI) treatment to reduce the occurrence of major cardiovascular events.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.